QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.049742v1 306/2/430    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neilan, C. L. Articles by Pasternak, G. W. Search for Related Content PubMed PubMed Citation Articles by Neilan, C. L. Articles by Pasternak, G. W.

NEUROPHARMACOLOGY

Characterization of the Binding of [³H][Dmt¹]H-Dmt-D-Arg-Phe-Lys-NH₂, a Highly Potent Opioid Peptide

Laboratory of Molecular Neuropharmacology, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (C.L.N., A.J.J., E.B., G.W.P.); and the Laboratory of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, Montreal, Canada (I.B., T.M.-D.N., P.W.S.)

The dermorphin-derived peptide [Dmt¹]DALDA (H-Dmt-D-Arg-Phe-Lys-NH₂; Dmt, 2',6'-dimethyltyrosine) labels µ-opioid receptors with high affinity and selectivity in receptor binding assays. In previous studies, [Dmt¹]DALDA displayed a mechanism of action distinct from that of morphine, as evidenced by its insensitivity to antisense probes reducing morphine analgesia and incomplete cross tolerance to morphine. In an effort to further elucidate the unusual mechanism of action, [³H][Dmt¹]DALDA has been synthesized and its binding profile studied. [³H][Dmt¹]DALDA binding was high affinity (K_D = 0.22 nM) and showed a regional distribution consistent with µ-receptors with highest levels in calf striatal membranes. [³H][Dmt¹]DALDA binding was far less sensitive than [³H][D-Ala²,N-Me-Phe⁴,Gly⁵-ol]-enkephalin (DAMGO) to the effects of divalent and sodium cations and guanine nucleotides, although NaCl and guanosine 5'-(,-imido)triphosphate together reduced specific [³H][Dmt¹]DALDA binding levels by almost 75%. Competition studies confirmed the µ-selectivity of the binding, with K_i values that were not appreciably different from those seen against [³H]DAMGO. In guanosine 5'-O-(3-[³⁵S]thio)-triphosphate ([³⁵S]GTPS) binding assays in brain and spinal cord membranes, [Dmt¹]DALDA was more potent than DAMGO, but showed plateaus suggestive of a partial agonist. [Dmt¹]DALDA bound to µ-opioid receptor clone 1 (MOR-1) and its splice variants with high affinity. Unlike [³H]DAMGO, [³H][Dmt¹]DALDA seemed to label both agonist and antagonist conformations of MOR-1 expressed in Chinese hamster ovary cells. In [³⁵S]GTPS assays [Dmt¹]DALDA showed high efficacy with all the MOR-1 variants, but its potency (EC₅₀) varied markedly among some of the splice variants despite similar affinities in receptor binding assays. Although [³H][Dmt¹]DALDA is a very potent µ-selective analgesic, its binding characteristics and its ability to stimulate GTPS binding differed from that of the classical µ-opioid peptide DAMGO.

Address correspondence to: Dr. Gavril Pasternak, Department of Neurology, 1275 York Ave., New York, NY 10021. E-mail: pasterng{at}mskcc.org

This article has been cited by other articles:

				B. G. Oertel, M. Kettner, K. Scholich, C. Renne, B. Roskam, G. Geisslinger, P. H. Schmidt, and J. Lotsch A Common Human {micro}-Opioid Receptor Genetic Variant Diminishes the Receptor Signaling Efficacy in Brain Regions Processing the Sensory Information of Pain J. Biol. Chem., March 6, 2009; 284(10): 6530 - 6535. [Abstract] [Full Text] [PDF]